BioX­cel touts healthy vol­un­teer da­ta for neu­ro ther­a­py; Io­n­is, Chi­nook part­ner on rare kid­ney dis­ease

BioX­cel Ther­a­peu­tics re­port­ed some new healthy vol­un­teer da­ta that it’s tout­ing as pos­i­tive.

The biotech said in a press re­lease Tues­day that its ex­per­i­men­tal BX­CL501 ther­a­py as an ad­junct for ma­jor de­pres­sive dis­or­der proved safe and tol­er­a­ble in a Phase Ib mul­ti­ple-as­cend­ing dose tri­al, re­sults that al­low re­searchers to se­lect a dose for Phase II. The max­i­mum tol­er­at­ed dose was not at­tained, CMO Robert Risinger said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.